A process transfer from a conventional system to a novel fixed-bed bioreactor
Third-generation lentiviral vectors (LVV) are used to deliver transgenic CAR sequence to patients T cells, playing a pivotal role in CAR-T cell therapy development. However, large-scale LVVs production faces many challenges due to high dosage demand and quality requirements. Therefore, it is crucial to have a production platforms that provides fast scale-up and a process able of producing high yields at a reduced cost per dose.
In this study, we report a process transfer of LVV production with adherent HEK293T cells from a conventional 2D system to a novel fixed-bed bioreactor.